Ximelagatran 是一种口服活性凝血酶抑制剂，可选择性的、竞争性的抑制游离和凝块结合的凝血酶。它是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。

Ximelagatran, a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.

Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran which is a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement[1].

192939-46-1

C24H35N5O5

473.57

H 37695;H-37695;H 376-95;H 376/95;EXANTA;希美加群;H37695

DMSO:55 mg/ml (116.14 mM)
H2O:Insoluble
H2O:Insoluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years